JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma

  • 0Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Cell +

|

May 26, 2015

|

May 26, 2015

View abstract on PubMed

Summary

This summary is machine-generated.

Pancreas cancer metastasis is often fatal. This study reveals how Dpc4/Smad4 and Runx3 mutations influence tumor growth versus spread, offering insights for tailored patient treatments.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • Pancreatic ductal adenocarcinoma (PDAC) frequently exhibits high metastatic potential, a primary cause of patient mortality.
  • Distinct PDAC phenotypes exist, including locally destructive disease and highly metastatic forms, necessitating a deeper molecular understanding.
  • Identifying the molecular drivers of these divergent disease behaviors is crucial for improving patient management strategies.

Purpose Of The Study

  • To investigate the molecular mechanisms underlying the differential metastatic potential and proliferation rates in pancreatic cancer.
  • To elucidate the roles of Dpc4/Smad4 and Runx3 in regulating the balance between tumor cell division and dissemination in PDAC.
  • To develop a predictive model for PDAC behavior based on genetic alterations to inform clinical treatment.

Main Methods

  • Utilized genetically engineered mouse models (GEMMs) of pancreatic ductal adenocarcinoma.
  • Analyzed the impact of heterozygous and homozygous loss of Dpc4/Smad4 on tumor characteristics in Kras(G12D/+);Trp53(R172H/+) models.
  • Assessed the expression levels and functional role of Runx3 in coordination with Dpc4 status.

Main Results

  • Heterozygous Dpc4/Smad4 mutation attenuated metastasis but increased proliferation in PDAC mouse models.
  • Subsequent loss of heterozygosity for Dpc4 restored metastatic capability while further enhancing proliferation, leading to a highly lethal phenotype.
  • Runx3 expression levels were found to be responsive to Dpc4 status, coordinating the balance between cancer cell proliferation and dissemination.
  • Runx3 demonstrated a dual role, acting as a tumor suppressor by slowing proliferation and a tumor promoter by orchestrating metastatic processes.

Conclusions

  • The interplay between Dpc4/Smad4 and Runx3 status significantly influences the balance between pancreatic cancer cell proliferation and metastasis.
  • A model is proposed to predict distinct PDAC disease behaviors based on these genetic factors.
  • These findings have implications for tailoring treatment strategies to individual patient profiles based on anticipated disease progression.